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modest.	However,	 an	 ethnic	 deviation	 (Ashkenazi	
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Core tip: The	 incidence	of	pancreatic	cancer	 increases	
with	 the	number	of	 family	members	with	pancreatic	
cancer	(PC).	Familial	pancreatic	cancer	(FPC)	is	defined	
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INTRODUCTION
Today, in both Japan and Unites States, the number 
of patients with pancreatic cancer (PC) is gradually 
increasing[1,2]. The nationwide cancer deaths due to 
PC is now total over 30000, so that PC ranks fourth 
among all human cancers (http://ganjoho.jp/reg_stat/
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statistics/dl/index.html#mortality)[1]. A survey by the 
Japanese Pancreas Society (2012) indicated an overall 
5 year survival for PC patients of only 13.0%. However, 
when treated when the tumor size is ≤ 10 mm or 
within UICC-Stage 0, the 5 year survival increases to 
80.4% and 85.8%, respectively[2]. The best strategy 
for curing this deadly cancer is currently thought to be 
early detection by following high-risk individuals and 
resection at a suitable time.
The risk factors for PC include image-detectable 
pancreatic diseases and lifestyle factors. The former 
includes pancreatic cysts[3,4], pancreatic duct dilation[3], 
intraductal papillary mucinous neoplasm (IPMN)[5], 
and chronic pancreatitis[6,7], while the latter includes 
smoking[8-10], diabetes mellitus[10-12], obesity[13,14], and 
low vitamin intake[15], among others. A family history 
of PC is another known risk, and one that cannot be 
modified by individual effort or by medicine.
Various human cancers show family history as a 
risk of the same cancer developing in related family 
members[16-18]. Several case-control studies and cohort 
studies have demonstrated an increased risk of PC 
in those who have a first degree relative (FDR) who 
is a PC patient [2.1[19]-5.3[20] of odds ratio (OR) and 
1.5[21]-1.7[22] of relative risk (RR)[23]]. The incidence 
of PC increases with the number of family members 
with PC, so that persons with one FDR with PC have 
a 4.5 fold increased risk of PC, those with two FDRs 
have a 6.4 fold increased risk, and those with three or 
more FDRs have up to a 32 fold risk[24]. The presence 
of two or more pancreatic cancer patients within FDRs, 
and without association with known hereditary genetic 
syndromes, is defined as familial pancreatic cancer 
(FPC).
The incidence of FPC among total cases of PC is 
4%-10%. However, highly affected families are rare 
(i.e., families with three or more PC cases within FDRs 
account for only 0.5% of all PC cases in Japan)[10], 
and their inherited risk is not as high as that of other 
human malignancies (e.g., melanoma, prostate cancer, 
ovarian cancer, and breast cancer) as confirmed by a 
study of a large number of twins in Nordic countries[25]. 
Several environmental factors (tobacco smoke, 
asbestos, radon)[10,26] have been reported in cases of 
FPC, and we must bear in mind that “familial PC” is 
not a synonym for “inherited PC”. With the mentioned 
criteria, pathogenic germline mutation has been 
proven in less than 20% of FPC cases, and this is far 
lower than is observed in other familial cancers asso-
ciated with the pancreatic neoplasms, such as multiple 
endocrine neoplasia type 1 (MEN1) and von Hippel-
Lindau disease.
Higher risks of PC are also associated with some 
inherited syndromes, such as Peutz-Jeghers syndrome 
(PJS)[27], hereditary pancreatitis (HP)[28-31], familial 
atypical multiple mole melanoma (FAMMM)[32,33], 
hereditary breast-ovarian cancer (HBOC)[34-37], heredi-
tary nonpolyposis colorectal cancer [HNPCC, Lynch 
syndrome (LS)][38,39], familial adenomatous polyposis 
(FAP)[40], and Werner syndrome[41] (Table 1). However, 
these syndromes are excluded from the definition of 
FPC in its narrowest meaning. In western countries, 
high risk individuals (HRI) with a family history of PC 
and hereditary cancer syndromes have been partici-
pating in nationwide or institutional FPC registries[42], 
and clinical surveillance and basic research have been 
performed to detect PC in its early stage. This review 
has focused on the concept and the current outcomes 
of surveillance of HRI.
CHaRaCTeRISTICS Of fpC
Epidemiology
FPC has several epidemiological features that distin-
guish it from ordinary PC. Similar to other familial 
cancers, FPC shows a trend toward a younger onset 
[FPC: age 58[43]-68[44], compared to sporadic PC (SPC): 
age 61[43]-74[44]] and an ethnic deviation (Ashkenazi 
Jewish > Caucasian)[34]. The lifetime risk of PC also 
increases with decreasing age of onset of PC in family 
members[44,45]. Meanwhile, similar to the sporadic 
cases, smoking (especially current smoking)[10,26] and 
diabetes (recent onset of diabetes)[10] are also risks for 
FPC.
A pedigree of FPC also incurs an increased risk of 
developing cancer or cancer death from diseases other 
than PC, such as in melanoma (OR = 16.8, P < 0.0001), 
endometrial cancer (OR = 5.26, P = 0.034), breast 
cancer [weighted standardized mortality ratio (wSMR): 
1.7], ovarian cancer (wSMR: 2.1), and bile duct cancer 
(wSMR: 3.0)[46]. Several studies have also demon-
strated an unexplained worse prognosis in familial 
cases than in sporadic cases[26,47], albeit some showed 
no difference[48]. Surprisingly, two European registries 
(EUROPAC[30] and FaPaCa[49,50]) that analyzed 106 
FPC families (264 affected individuals) through three 
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Table 1  Relative risk of pancreatic cancer in hereditary cancer syndromes
Inherited syndrome Relative risk Cumulative risk of PC Responsible gene
Peutz-Jeghers syndrome[27] 132 11%-36% STK11
Hereditary pancreatitis[28-31] 53-87 40%-55% PRSS1
Familial atypical multiple mole melanoma[32,33] 13-22 17% CDKN2A
Hereditary breast-ovarian cancer syndrome[34-37,73]   4-13 2%-7% BRCA1, BRCA2
Lynch syndrome[38,39] 5-9   4% MLH1, MSH2, MSH6, PMS2
Familial adenomatous polyposis[40]     5 - APC, MUTYH
PC: Pancreatic cancer.
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generations [dates of birth: 1900-1919, 1920-1939, 
1940-1969] observed “anticipation” in the affected 
kindred of FPC patients[51]; that is, a trend existed 
toward younger age and worse prognosis in the latest 
generation.
Pathology and molecular biology
As is found with colorectal polyposis in numerous 
FAP patients, the pancreatic histology of FPC kindred 
often demonstrates multiple precancerous lesions[48] 
or pancreatic intraepithelial neoplasias (PanINs)[52,53]. 
PanINs with various mutations of KRAS codon 12 are 
frequently recognized in the vicinity of ordinary PC[54]; 
however, they are 2.75-fold more frequent in the FPC 
than in the SPC pancreas[55]. These precursor lesions 
sometimes appear in the clinical image as small cystic 
lesions[52,56] and are more often recognized in the pan-
creases of FPC families than in those of CDKN2A/p16 
mutation carriers (By contrast, PC is 10 times more 
frequent in the latter group)[57]. These lesions in FPC 
kindred are associated with lobular parenchymal atro-
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phy and chronic pancreatitis-like changes observable 
by endoscopic ultrasonography (EUS)[53].
Despite the difference in the numbers of precursor 
lesions[48,53], a blind review of histological observation 
of 519 FPCs and 561 SPCs by expert pathologists did 
not show any significant difference in terms of tumor 
size, location, neural invasion, angiolymphatic invasion, 
lymph nodal metastasis, and pathological stage[58]. 
The genome-wide allelic status[59,60], and genetic and 
epigenetic alterations[61] are also similar between SPC 
and FPC.
geNeTICS aND ClINICal maNagemeNT 
Of fpC
Familial pancreatic cancer registry
Figure 1 shows a global map of the institutional and 
nationwide pancreatic cancer registries, including 
FPC registries. The National Familial Pancreas Tumor 
Registry (NFPTR) (http://pathology.jhu.edu/pan-
creas/nfptr/history.php) was founded in 1994 at Johns 
Figure 1  Worldwide mapping of the (familial) pancreatic cancer registries and genetic research institutions (1-24). 1: Memorial Sloan-Kettering Cancer Center, 
Familial Pancreatic Cancer Family Registry; 2: Johns Hopkins University, National Familial Pancreas Tumor Registry; 3: Indiana University, Familial Pancreatic Cancer 
Registry; 4: NorthShore University, Pancreatic Cancer Family Registry; 5: Northwestern University, Pancreatic Cancer Family Registry; 6: University of Nebraska 
Medical Center and Creighton University, Pancreatic Cancer Family Registry; 7: Huntsman Cancer Institute and University of Utah, Familial Pancreatic Cancer 
Registry; 8: University of Washington, Familial Pancreatic Cancer Registry; 9: Columbia University, Pancreatic Cancer Registry; 10: Thomas Jefferson University, 
Jefferson Pancreas Tumor Registry; 11: University of Oklahoma, National Pancreatic Cancer Registry; 12: Oregon Health & Science University, Oregon Pancreas 
Tumor Registry; 13: Dana-Farber Cancer Institute, Pancreatic Cancer Genes Study; 14: University of Pittsburgh, Pancreatic Adenocarcinoma Gene-Environment 
Risk Study and Registry; 15: Karmanos Cancer Center and Wayne State University, Pancreatic Cancer Genetic Study; 16: Mayo Clinic, Pancreatic Cancer Genetic 
Study; 17: University of Texas and MD Anderson Cancer Center, Pancreatic Cancer Genetic Study; 18: Mount Sinai Hospital, Toronto, Familial Gastrointestinal 
Cancer Registry; 19: Philipps University of Marburg, German National Case Collection Familial Pancreatic Cancer; 20: University of Liverpool, European Registry of 
Hereditary Pancreatitis and Familial Pancreatic Cancer; 21: National Registry for Familial Pancreatic Cancer in Italy; 22: Ramon y Cajal University Hospital, Madrid, 
Spanish Registry of Hereditary Pancreatic Cancer; 23: The  Kinghorn Cancer Center, Australian Pancreatic Cancer Genome Initiative; 24: Kyoto University, Japanese 























Hopkins University (Baltimore, United States)[62]. This 
was followed by the European Registry of Hereditary 
Pancreatitis and Familial Pancreas Cancer (EUROPAC: 
http://www.europac-org.eu/)[30] (1997) at Liverpool 
University (Liverpool, United Kingdom) and the 
German National Case Collection for Familial Pancreatic 
Carcinoma (FaPaCa: http://www.fapaca.de/)[49,50] 
(1999) at Phillips University (Marburg, Germany). The 
NFPTR had enrolled 4322 families as of 2012; of these, 
1376 families had one or more cases of PC in their 
FDRs. The FaPaCa had 452 registered FPC families 
as of 2009[49]. National FPC registries have also been 
established in Italy (2007)[63] and in Spain (2009)[64]. 
In Japan, a kickoff meeting was held at Kyoto among 
international experts in October 2012[65]. A committee 
was assembled in 2013 and the nationwide registry 
of FPC (Japanese Familial Pancreatic Cancer Registry: 
JFPCR: http://jfpcr.com) was officially established in 
2014 by the Japan Pancreas Society.
Consortiums and symposiums have also been orga-
nized among several high volume centers and/or FPC 
registries in North America [Pancreatic Cancer Genetic 
Epidemiology Consortium (PACGENE) in 2002, funded 
from the National Cancer Institute][62] and across the 
globe [International Symposium on Inherited Diseases 
of the Pancreas[66] initiated in 1997, Pancreatic 
Cancer Cohort Consortium (PanScan) in 2006[8,67], 
and International Cancer of the Pancreas Screening 
Consortium (CAPS) in 2011[68]]. The aim has been 
to gather information on patients and families of PC 
and to study the cause of PC, with the ultimate goal 
of improving the clinical practice of counseling and 
screening of the HRIs, and to devise new early detec-
tion methods for PC and better treatments. To date, a 
large number of clinical studies have been conducted 
under the FPC registries, mostly concerning risk 
assessment and screening of family members of FPC 
patients, in parallel with basic research on pancreatic 
carcinogenesis[69].
Genetics associated with familial pancreatic cancer
The establishment of FPC registries was followed 
by a long period of basic research on FPC, as well 
as pursuit of its causative genes[62]. As already 
mentioned, several hereditary cancer syndromes 
have increased risks for the development of PC (Table 
1)[23,70]. Genes responsible for FPC have included ATM 
(mutation rate: 2.4%)[71], BRCA1 (0-1%)[72,73], BRCA2 
(8%-19%)[35,74,75], CHEK2 (2.9%)[76], and PALB2 
(3.1%-3.7%)[77,78]. However, the known germline 
mutations account for less than 20% of FPC cases. 
These genes all function in the homologous recombi-
nation of the double strand DNA repair system, or the 
so-called Fanconi anemia (FA) pathway[79,80], and their 
germline mutations have also been reported in familial 
breast cancers[81].
BRCA1/2 mutation carriers have a mild to moder-
ate level of risk for PC (relative risks: 2-8, lifetime 
risks: 2%-17%), but some specific mutation types 
may have further increased risks. For instance, BRCA2 
6174delT, which is a Jewish founder mutation, was 
detected in 13% (3/23) of Jewish PC cases and the 
odds for having PC was 12.8[82]. Similarly, the BRCA2 
K3326X mutation was detected in 5.6% (5/144) of 
American FPC cases[83]. A murine model confirmed 
that a germline BRCA2 mutation suffices to promote 
carcinogenesis by the KRAS mutation[84], which is 
recognized in nearly 90% of PC cases[54]. This may also 
explain the function of BRCA2 mutation in FPC. Other 
genes working in conjunction with FA complementation 
groups, such as FANCA[85], FANCC[86], and FANCG[86], 
have been reported to show very low incidences of 
mutation in FPC (0%-0.5%).
Most recently, the PACGENE study group, which 
included six American and Canadian institutions, 
used custom genotyping arrays (iSelect Collaborative 
Oncological Gene-Environment Study array: iCOGS 
array) to analyze a single nucleotide polymorphism of 
985 PC cases [906 cases with a family history of PC 
and 79 cases with early-onset (≤ 50 years old)]. This 
group discovered evidence supporting an association 
of two genetic loci with PC: 7p21.1 (HDAC9) and 
21q22.3 (COL6A2)[87].
SURVeIllaNCe Of HIgH RISK 
INDIVIDUalS
Surveillance conditions
Screening the high-risk population is thought to be an 
effective strategy for early diagnosis of PC; however, 
several issues concerning screening have been 
raised[68]. These include the nature of the pathological 
lesion that represents the best target for surgical 
resection, the degree of risk expected for the scree-
ning, the best modality or combination of multiple 
modalities, the best age for initiating screening, the 
optimal screening interval, and the cost benefit and 
mental burden for the subjects.
Targeted pathological lesions: The CAPS con-
sortium summit held in Baltimore (2011) concluded 
that the success of a screening program for HRIs is 
defined as the detection and treatment of high-grade 
precursors (PanIN[52] and IPMN[88]) - UICC-stage ⅠA PC 
(T1N0M0; limited to the pancreas and no more than 
2 cm in size)[68]. Today, the overall survival of UICC-
stage ⅠA cancer is unsatisfactory (5-year survival: 
68.7%). The ideal for a targeted lesion is thought 
as high-grade precursors - UICC-stage 0 PC (5-year 
survival: 85.8%)[2].
Screening candidates and lifestyle guidance at 
surveillance: A high predictive value can be obtained 
by surveillance if the conditions of the high-risk group 
enrolled in a screening protocol are well examined. 
This is important from the viewpoint of the advantage-
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Table 3  Non-genetic risk factors of pancreatic cancer
disadvantage balance, especially concerning the eco-
nomic and mental burden placed on the individuals who 
undergo this surveillance.
The risk level of the candidate individual is assessed 
based on the numbers of affected family members[24] 
and hereditary syndromes (Table 1). “PancPro”[89,90] is 
free software for estimating PC risk (based mainly on 
hereditary risk) that uses prospective data obtained 
from 961 families enrolled in the NFPTR; this software 
is actually applied to the screening programs in 
Italy[90]. The international consortiums recommended 
that an individual who had a 5[68,91] to 10[66,92-95] fold 
risk undergo PC screening. However, we must bear 
in mind that a complete view of the genetic suscep-
tibility of PC is still unavailable and huge amounts of 
data from whole genome sequencing are needed for 
accurate assessment. At present, the CAPS consortium 
has proposed nine conditions for candidate HRIs (Table 
2), within a setting of greater than a 5-fold risk or a 5% 
of lifetime risk of PC[68].
A screening strategy should also evaluate the risk 
factors of lifestyle and pancreatic diseases, such as 
smoking[8,10,26,66,96], obesity[13,14,66], physical inactivity[14], 
diabetes[10-12,66], chronic pancreatitis[6,7,66], IPMN[88], 
pancreatic cyst[3,4], pancreatic duct ectasia[3], etc. (Table 
3). For instance, a patient with diabetes mellitus and 
a smoking history and a patient with one FDR with PC 
each showed a 10-fold risk when compared with nega-
tive controls[10]. The initial counseling should be used 
to present modifiable risks related to the lifestyle to 
HRIs and their improvement should be recommended; 
i.e., smoking cessation, a healthy diet high in fruits 
and vegetables, higher intakes of vitamin D (> 600 
IU)[15], and regular exercise to control weight (body 
mass index: < 25 kg/m2)[66].
Modalities of screening: Consensus could not be 
reached at the international consortium regarding the 
modality that is the most suitable for screening[66]. 
Many institutions currently use EUS as their standard 
modality[70], based on its ability to detect small 
pancreatic lesions (< 1 cm)[97-100]. Kamata et al[100] pro-
spectively compared the sensitivity of detecting a PC 
using EUS, enhanced computed tomography (CT), or 
magnetic resonance imaging (MRI) during the screen-
ing of 167 consecutive cases of IPMN; these authors 
concluded that EUS had the best sensitivity. EUS is also 
superior at detecting risk findings frequently seen in 
HRIs, such as duct ectasia, cysts[3], and subtle paren-
chymal findings of the pancreas[53,97,100-102]. However, 
agreement is poor in terms of these characteristic 
findings, even among expert endosonographers[103]. 
First, visualization by EUS largely depends on the 
operator’s skill[104]. The choice of EUS scopes is also 
contentious[105], as convex and radial types each have 
their own different peculiarities[106]. Other drawbacks 
of EUS include the necessity for a relatively long-time 
fasting period and conscious sedation, with a limited 
observation area in cases with a reconstructed upper 
gastrointestinal tract. In this sense, abdominal ultraso-
nography is a handy tool that may substitute for EUS if 
visualization of the pancreas is good without any blind 
spots[3], for the subjects with slim abdominal trunk.
MRI or magnetic resonance cholangiopancreatog-
raphy (MRCP) is good at visualization of the pancreatic 
ductal systems. Dilation of the pancreatic duct and cyst 
formation are risk factors for PC[3,4] and are actually 
frequently recognized in HRIs (cyst in 38.9% and duct 
ectasia in 2.3%)[102], making MRCP a promising tool for 
assessing the risk level of HRIs. CT scans have a high 
spatial resolution; however, the healthy examiners 
are exposed to radiation. Long-term screening for 
breast cancer with low-dose radiation may possibly 
increase the incidence of cancer in BRCA mutation 
carriers (BRCA1: < 2%, BRCA2: < 4%)[107]. This risk 
is especially high when radiation exposure occurs at 
age 20 or younger (OR = 2.0, 95%CI: 1.3-3.1) or 
is repeated five or more times (OR = 1.8, 95%CI: 
1.1-3.0)[108]. Excessive use of CT should be avoided 
in a BRCA mutant cohort. Endoscopic retrograde 
cholangiopancreatography (ERCP) is too invasive for 
routine screening and carries its own risk of procedure-
associated pancreatitis; nevertheless, it is used for fur-
ther investigation as it has the advantage of obtaining 
pathological samples[42,109-111]. Repeated pancreatic 
juice cytology with placement of endoscopic naso-
pancreatic duct drainage is effective for detecting early 
pancreatic carcinoma or carcinoma in situ spreading 
within the pancreatic duct[109]. EUS-guided fine needle 
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Table 2  Screening candidates with high risks1
Individuals with ≥ 3 affected relatives, with ≥ 1 affected FDR
Individuals with ≥ 2 affected FDRs with PC, with ≥ 1 affected FDR, 
reaching a certain age
Individuals with ≥ 2 affected relatives with PC, with ≥ 1 affected FDR
Peutz-Jeghers syndrome patients, regardless of family history of PC
CDKN2A mutation carriers with one affected FDR
BRCA2 mutation carriers with one affected FDR
BRCA2 mutation carriers with two affected family member pf PC 
PALB2 mutation carriers with one affected FDR
Mismatch repair gene mutation carrier (lynch syndrome) with one 
affected FDR
1Quoted from the reference[69]. FDR: First-degree relative; PC: Pancreatic 
cancer.
Factors Risk level
Smoking[8-10]        OR = 1.5-2.2
Diabetes[11,12]         RR = 1.8-1.9
Obesity[13,14]         RR = 1.1-1.4
Chronic pancreatitis[6,7]      SIR = 13-14
Intraductal papillary mucinous neoplasm[5] SIR = 16
Dilated main pancreatic duct [3]  HR = 6.4
Pancreatic cyst[3,4] HR = 6.2; OR = 10.3
SIR: Standardized incidence ratio.
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aspiration (EUS-FNA) can target small invasive carci-
noma, although only limited tissues can be obtained 
from carcinoma in situ, and dissemination is a risk[112].
In summary, EUS and MRI are considered the most 
accurate image tools[100-102,113] with high agreement 
among the consortium experts (agreement, EUS: 
83.7% and MRI/MRCP: 73.5%)[68]. EUS-FNA and 
ERCP are applicable when abnormal findings or their 
changes are observed in other images[42,97]. In addition 
to image analysis, serum tumor markers, including 
elevated carcinoembryonic antigen and CA19-9, should 
be checked each time[42,49,50,68].
When to start screening: Screening in many institu-
tions is started at 40 years of age[64,97] or 10 years 
younger than the age of the youngest relative with 
PC[42,49]. As PC develops in cases of PJS at a young age 
(40.8 years)[27], screening is started at 30 years old[97]. 
However, detection of pancreatic lesions increases 
after age 50-60[102,114]. No consensus has been reached 
regarding the age to initiate screening and more than 
half (51%) of the experts in CAPS consortium voted 
the initial screening at age 50[68].
Screening interval: Many institutions opt for yearly 
screening[42,50,95,97,114] if the latest EUS and/or CT is 
normal (73.5% of agreement by CAPS consortium)[68]. 
Once an abnormal finding is observed, subsequent 
screening is done every 3-6 mo[50,97] or 3-12 mo[42,68]. 
The endorsed screening interval for a non-suspicious 
cyst is 6-12 mo (agree: 83.7%), 3 mo for a newly 
detected solid lesion if surgery is not imminent (agree: 
85.7%), and 3 mo for an indeterminate main pan-
creatic duct stricture (agree: 95.9%)[68]. The natural 
history and progression of FPC still require study to 
determine the appropriate duration for screening 
intervals in relation to the risk level.
Surgical indications and procedures: As already 
mentioned, the characteristics of pancreatic histology 
in FPC kindred are multifocal PanINs or IPMNs[55] asso-
ciated with duct ectasia and parenchymal atrophy[53]. 
The surgical indication for IPMN lesions can be deter-
mined according to established Fukuoka guidelines[88]. 
However, detection of PanIN3 (carcinoma in situ) or 
minimally invasive cancer is difficult, as these cancers 
are tiny and do not form a solid mass or a nodule.
The extent of resection is controversial, depending 
on the therapeutic concept. The choices are to remove 
all precancerous lesions[42] or to resect only a targeted 
area that includes nodular or cystic lesions[97,115]. In 
cases of HBOC with the BRCA mutation, risk-reducing 
salpingo-oophorectomy is affordable and has an 
acceptable level of complications[116]. However, for 
the pancreas, total pancreatectomy (TP) has severe 
complications, including a considerable level of 
postsurgical in-hospital mortality (cf. nationwide: 23%, 
high-volume hospital: 5%, in Germany)[117,118] and 
subsequent serious glycemic control failure (mortality: 
4%-8% per year)[119]. A secondary pancreatectomy 
for the remnant pancreas can be conducted without 
increasing morbidity and mortality[120], so resection of 
the target area, rather than TP, has been preferable 
thus far.
For many years, TP with pancreatic transplantation 
has been conducted in patients with type 1 diabe-
tes[119] and TP combined with islet autotransplantation 
has been performed on chronic pancreatitis patients 
with intractable pain[121]. However, most recently, due 
to the improvements in post-surgical quality of life, 
these treatment procedures have been considered and 
actually indicated for FPC kindred with premalignant 
lesions[119,122,123]. Further improvements are expected in 
the future.
Present outcomes of surveillance of high risk 
individuals
Several surveillance results have been reported 
from single or collaborated FPC registries in western 
countries; their protocol conditions and outcomes 
are summarized in Table 4[42,50,91,92,94,95,97,101,114,124-127]. 
Some of the cases from the same registry may appear 
in more than one report; therefore, interpretation of 
cumulative data needs caution. About 5%-20% of 
the screened HRIs underwent surgery for suspected 
lesions. Roughly one third of the resected cases were 
benign lesions that underwent unnecessary treatment, 
and only less than one fifth were borderline precursors 
and carcinoma in situ, or definitive targets of the 
surveillance (Table 4). A small proportion of PC was 
resected at an early phase (T1N0M0)[94], but some 
PC cases were detected at the advanced unresectable 
stage. These outcomes testified to the difficulty of 
providing an accurate diagnosis of PCs at the curative 
stage.
Psychological and economical aspects of surveillance
Screening participants who are FPC kindred commonly 
express grief from the experience of family death due 
to PC[128-130], and are distressed by the high mortality 
and uncertainty related to prevention and early detec-
tion[128]. Their motivation for participating in surveil-
lance is “possible early detection of (a precursor stage 
of) PC” (95%-100%)[131], and they want to control 
their cancer risk by seeking information and resources 
to prevent PC[128]. Research conducted by the Mayo 
Clinic indicated that 67% (238/361) of FPC kindred felt 
they had a higher lifetime risk of PC when compared 
to people of the same age, race, and gender, and 95% 
were likely to undergo blood test surveillance and 75% 
were likely to undergo EUS surveillance[130]. A study at 
the University of Toronto revealed that the perception 
of PC risk was higher in FPC kindred than in BRCA2 
mutation carriers (42% vs 15%)[129]. Most participants 
had anxiety and worry at the beginning, although 
only occasionally or sometimes[128,130]; however, this 
gradually decreased as surveillance progressed (over 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The “doing nothing” strategy provided the lowest 
cost, the greatest remaining years of life, and the 
best quality-adjusted life years, when compared to 
the smallest benefit in these aspects obtained with 
prophylactic TP.
CHemOTHeRapY fOR famIlIal 
paNCReaTIC CaNCeR WITH BRCA 
mUTaTION
For unresectable PC, on the basis of current evidence, 
FOLFIRINOX (fluorouracil, folic acid, irinotecan, and 
oxaliplatin) and gemcitabine-based regimens are 
standard choices of chemotherapy (median survival: 
11 mo and 6-9 mo, respectively)[70]. However, in 
agreement with the response observed in HBOC 
patients[137-139], PC patients with BRCA1/2 mutation 
carriers respond well to platinum-based chemo-
therapy[140] and poly (ADP-ribose) polymerase (PARP) 
inhibitors[138,141], as determined in several studies. For 
example, Golan et al[140] compared overall survival (OS) 
of 43 patients with stage Ⅲ-Ⅳ PC with BRCA mutation 
carriers in terms of their chemotherapy regimen-either 
platinum or non-platinum. Superior OS was observed 
for patients treated with platinum chemotherapy (n 
= 22) than with non-platinum (n = 21) (22 mo vs 
9 mo, P = 0.039). A similar effect was confirmed in 
an experiment using xenografts by Lohse et al[142], 
who reported that PC xenografts harvested from 
BRCA mutation carriers and implanted into nude mice 
showed sensitivity to both gemcitabine and cisplatin. 
By contrast, xenografts from BRCA wild cases showed 
sensitivity only to gemcitabine. A joint study by Johns 
Hopkins University and the MD Anderson Cancer 
Center[143] analyzed effectiveness of platinum-based 
chemotherapy in metastatic PC patients (n = 549) by 
familial cancer history, although germline BRCA status 
was not described, and demonstrated a superior OS in 
patients with family history of either breast, ovarian, 
or pancreatic cancer (HR = 0.49, P = 0.003). Survival 
was strongly associated with the number of relatives 
with BRCA-related malignancy (P = 0.009).
Kaufman et al[138] reported that a PARP inhibitor 
(PARPi) treatment induced a 22% response ratio with 
4.6 mo of progression-free survival in BRCA-mutant PC 
patients who had already showed progression resistant 
to the gemcitabine treatment. PARPi is effective for PC 
cases with deficiency in the homologous recombination 
pathway; i.e., in cases with either mutation of ATM, 
BRCA1, BRCA2, or CHEK2. This outcome is explained 
by a synthetic lethal theory, where apoptosis is induced 
by blocking both the single- and double-strand DNA 
break repair system[139]. Currently, data are lacking 
with respect to PARPi use against FPC in causative 
mutation carriers. Future outcomes are expected.
CONClUSION
In addition to classical risk factors, hereditary factors 
including family history of pancreatic cancer and some 
genetic syndromes must be taken into account when 
screening to detect early pancreatic cancer. Since the 
1990s, basic and clinical research has accumulated 
much scientific data on FPC. However, to date, scree-
ning of HRIs has had unsatisfactory outcomes. In 2014, 
the JFPCR was established in Japan, and projects have 
just begun for early detection and better outcomes of 
PC. Success in this venture will depend on improve-
ment of all aspects, including genetic medicine, scree-
ning and treatment methods, and better understanding 
of what determines a HRI.
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